Carbidopa

CAS 38821-49-7

About the API

Systematic name (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
Trade name(s) Lodosyn Appearance
Technology Synthetic Organic Chemistry
Molecular Formula C10H14N2O4
Molecular Weight 226.2291 g/mol (anhydrous)
Therapeutic category Parkinson
Available formulations Oral Liquid Oral Solid Oral Solid Long-Acting Other Systemic
Regulations Canada DMF Flag Canada DMF CEP Flag CEP EU DMF Flag EU DMF Japan DMF Flag Japan DMF Other Flag Other US DMF Flag US DMF

General Information

Carbidopa, classified as a non-competitive decarboxylase inhibitor, is used in combination with the chemically related levodopa for the treatment of Parkinson’s disease or Parkinson-like symptoms (e.g. stiffness, shakiness, difficulty moving). Used alone, carbidopa has no effect on Parkinson’s symptoms. It is used to improve the effect of levodopa and reduce unwelcome side effects such as nausea. The drug works by preventing the breakdown of levodopa in the bloodstream, which allows more levodopa to enter the brain. Carbidopa has no anti-Parkinson effects by itself.

 

Presently, carbidopa is prepared by large-scale semi-synthetic methods. Semi-synthesis is a type of chemical synthesis that makes use of compounds derived from natural sources (bacterial; cell cultures; plant material) as starting material. Levodopa, a semi-synthetic product itself, can be easily converted to carbidopa in a single step.